Skip to main content
Premium Trial:

Request an Annual Quote

Quest Diagnostics Lymphocyte-activation gene 3 Immunohistochemistry Assay

Quest Diagnostics has launched an immunohistochemistry assay that measures Lymphocyte-activation gene 3 (LAG-3) expression to guide treatment in patients with melanoma. The assay is intended to assess the LAG-3 status in patient tumors and to correlate between expression status and response to LAG03 immunotherapy.